# Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients

> **NCT04440436** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing Immunochina Medical Science & Technology Co., Ltd.** · enrollment: 52 (estimated)

## Conditions studied

- NHL

## Interventions

- **DRUG:** IM19 CAR-T Cells

## Key facts

- **NCT ID:** NCT04440436
- **Lead sponsor:** Beijing Immunochina Medical Science & Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-06-04
- **Primary completion:** 2022-06-04
- **Final completion:** 2035-06-04
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2020-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04440436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04440436, "Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04440436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*